Company intelligence / Profile preview

TCT International

Istanbul, Türkiye

Ownership: Private
Development stage: Other

Overview

TCT Health Technology is pioneering locally produced CAR-T cell therapies in Türkiye, with a focus on CD19-targeted hematologic cancers. Their zCAR-T platform has shown nearly 90% complete remission in Phase II trials. AT101, a next-generation CAR-T therapy licensed from AbClon, is being transferred for local production and clinical development in Türkiye.

Therapeutic areas: Oncology
Modalities: CAR-T cell therapyGene therapyCell therapyPrecision medicine
Industry: Biotech

Partnerships

AbClon (South Korea)CytivaTurkish Health Institutes (TÜSEB)Royal Institute of Technology (Sweden)Erciyes UniversityKoç UniversityTÜBİTAK MAM

Beyond the preview

Go deeper on TCT International.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TCT International.

Explore the full profile